Recent research highlights the dual role of a crucial enzyme in our immune system known as the apolipoprotein B mRNA-editing enzyme, catalytic polypeptide, or more commonly, APOBECs. A program aired on April 7, 2024, delved into how these enzymes can both protect against viral infections and inadvertently contribute to cancer progression.
Dr. Reuben S. Harris, Chair of the Department of Biochemistry and Structural Biology at the University of Texas Health Science Center at San Antonio, leads a laboratory dedicated to exploring the functions of APOBECs. “From the virus perspective, these enzymes protect us,” Harris explained. They are DNA mutating enzymes that typically serve as defenders against invading viruses. However, in cancer, their function can become dysregulated, leading to harmful mutations within our genomes.
“This is where the good guys can become villains,” Harris stated. The unintended consequences of APOBEC activity can result in catastrophic damage to healthy cells. In cancer treatment, surgical resection of tumors is often a frontline standard of care. Harris proposes that during this critical time, it could be beneficial to inhibit APOBEC enzymes to prevent further genomic damage.
After the removal of an APOBEC-positive tumor, Harris suggests that shutting off these enzymes could significantly lower the risks of cancer recurrence, metastasis, or the development of medication resistance. “If we can stop that, we can make all of these adverse events much less likely to happen,” he noted. This potential therapeutic approach excites the research community, as it presents a new avenue for improving cancer outcomes.
Research on APOBEC enzymes not only advances our understanding of cancer biology but also paves the way for innovative treatment strategies. The collaboration between TPR and the University of Texas Health Science Center emphasizes the importance of scientific discovery in enhancing medical practices globally. As researchers continue to investigate the complexities of APOBECs, the hope is to transform their role from a source of genomic instability to a target for therapeutic intervention.
